Table 1

Clinical studies on target volume during pressure-preset ventilation

StudyYearDesignCohortTarget volume settingMain target volume outcomes*
Storre et al7 20066-week cross-over RCT (n=10)OHS7 ml/kg IBW (n=5), 10 ml/kg IBW (n=5)
  • Greater reduction in nocturnal PtcCO2

  • Comparable effect on polysomnography

  • Comparable effect on quality of life

Janssens et al10 20091-day cross-over RCT (n=12)OHS7.5±0.8 ml/kg body weight
  • Greater reduction in nocturnal PtcCO2

  • Worse polysomnography

Ambrogio et al11 20091-day cross-over RCT (n=28)Mixed8 ml/kg IBW or 110% of baseline VT
  • Comparable effect on polysomnography

  • Greater nocturnal minute volume

Crisafulli et al12 20095-day cross-over RCT (n=9)COPD8 ml/kg IBW
  • Comparable improvements in morning PaCO2

  • Subjective improvement in sleep efficiency

Oscroft et al13 §20108-week cross-over RCT (n=24)COPD11.0±3.9 l/min (minute volume)
  • Comparable effects on:

    • Daytime blood gases

    • Lung function and exercise capacity

    • Quality of life

    • Nocturnal PtcCO2

Murphy et al14 20123-month RCT (n=46)OHSIndividual adjustments aimed at achieving control of nocturnal hypoventilation while abolishing obstructive events
  • Comparable effects on:

    • Daytime PaCO2 improvements

    • Quality of life

    • Weight loss

    • Comparable improvements in ESS

  • * Compared with conventional pressure-preset non-invasive positive pressure ventilation (NPPV).

  • Mode for target volume: average volume assured pressure support.

  • Patients naive to any form of NPPV.

  • § Mode for target volume: intelligent volume assured pressure support.

  • Patients already established on pressure-preset NPPV.

  • COPD, chronic obstructive pulmonary disease; ESS, Epworth Sleepiness Score; IBW, ideal body weight; OHS, obesity hypoventilation syndrome; PaCO2, arterial partial pressure of carbon dioxide; PtcCO2, transcutaneous partial pressure of carbon dioxide; RCT, randomised controlled trial; VT, tidal volume.